Back to Browse Journals » Blood and Lymphatic Cancer: Targets and Therapy » Volume 1

mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report

Authors Ibeas P, Cantos B, Provencio M.

Published Date November 2011 Volume 2011:1 Pages 19—22

DOI http://dx.doi.org/10.2147/BLCTT.S24910

Published 8 November 2011

Patricia Ibeas, Blanca Cantos, Mariano Provencio
Clinical Oncology Department, Hospital Puerta de Hierro Majadahonda, Madrid, Spain

Abstract: Hodgkin’s disease is curable in 90% of the cases diagnosed in early stages (I and II) and in 70% of all patients who suffer from the disease. Refractory disease occurs in 10%–15% of cases and is still a clinical challenge. Its treatment is based on intensive chemotherapy regimens with transplantation, but there are patients who relapse after transplantation who have a poor prognosis. At this point in time, there is a lack of effective treatment options with proven efficacy and there is a real need to investigate new treatment drugs with different mechanisms of action. A persistent activation of mTOR signaling has been identified in leukemia, Hodgkin’s and non-Hodgkin’s lymphoma, and multiple myeloma. Everolimus, an mTOR kinase inhibitor, is being used as an option in these cases with encouraging results. Here, the authors report their experience with a patient treated with everolimus.

Keywords: everolimus, positron emission tomography, chemotherapy

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Hyperuricemia and non-dipping blood pressure

Marrone O, Bonsignore MR

International Journal of Nephrology and Renovascular Disease 2013, 6:269-270

Published Date: 4 December 2013

The Treatment Effectiveness Assessment (TEA)

Ling W, Farabee D, Liepa D, Wu LT

Substance Abuse and Rehabilitation 2013, 4:73-74

Published Date: 24 September 2013

Effects of Arthro-7® in relieving symptoms of osteoarthritis with mild to moderate arthralgia [Corrigendum]

Xie Q, Zhou T, Yen L, Shariff M, Nguyen T, Kami K, Gu P, Liang L, Rao J, Shi R

Nutrition and Dietary Supplements 2013, 5:7-8

Published Date: 16 May 2013

Prescribing tests must have curriculum support

Lemon TI, Shah RD

Advances in Medical Education and Practice 2013, 4:91-93

Published Date: 7 May 2013

Pharmacogenomic considerations in opioid analgesia. [Corrigendum]

Vuilleumier PH, Stamer UM, Landau R

Pharmacogenomics and Personalized Medicine 2013, 6:1-2

Published Date: 14 January 2013

Letter to the editor

D'Alessandro V, Greco M

Journal of Blood Medicine 2012, 3:43-44

Published Date: 3 August 2012

Influence of microenvironment on cell adhesion, polarization, and migration

Pajic-Lijakovic I, Plavsic M

International Journal of Nanomedicine 2012, 7:3473-3474

Published Date: 6 July 2012

Integrins and extracellular matrix in mechanotransduction

Ramage L

Cell Health and Cytoskeleton 2012, 4:1-9

Published Date: 28 December 2011